Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

Hemophilia A, a lifelong bleeding disorder, often causes spontaneous or injury-related bleeding, most commonly in large ...

US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi ...

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its effectiveness in another group of patients with the bleeding disorder. | ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Pfizer (NYSE:PFE) announced Thursday that a late-stage trial for Hympavzi, its once-weekly injectable for bleeding disorder ...

In Hooghly district, haemophilia injections have not been available at either Chinsurah Imambara Hospital or Arambagh Medical ...

Scientists from Cincinnati Children's and colleagues based in Japan report achieving a major step forward in organoid ...